Mu opioid receptor–Alpha-2A adrenergic receptor heterodimer (MOR–α2AAR heterodimer)

The Mu opioid receptor–Alpha-2A adrenergic receptor heterodimer is a G protein-coupled receptor complex formed by physical interaction of MOR and α2AAR on neuronal membranes. This heterodimer engages in unique signaling behavior: activation of one protomer can regulate, inhibit, or modify the signaling of the partner receptor through allosteric, cross-conformational changes. The existence of MOR–α2AAR heterodimers introduces additional complexity in opioid and adrenergic pharmacology. Functional studies show that the heterodimer can modulate analgesic efficacy and tolerance, and may reduce excessive opioid-induced analgesia by permitting antagonistic signaling between MOR and α2AAR. The heterodimer may represent a novel therapeutic target in pain management and possibly in cardiovascular and neuropsychiatric disorders, though the physiological and clinical relevance is still an area of active research.

Other names

MOR–alpha-2A adrenoreceptor heterodimerMu opioid receptor–α2AAR heterodimerMu opioid–Alpha-2A adrenergic receptor complex

Agonist binding at either MOR or α2AAR within the heterodimer can allosterically modulate the activity of the partner receptor, often resulting in antagonistic crosstalk (activation of one can inhibit signaling of the other) Combined agonist activation may counteract excessive analgesia Drugs targeting the heterodimer may yield distinct pharmacological outcomes compared to either receptor alone, potentially addressing opioid tolerance or improving pain management